- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Founding
The company was founded by Remi Barbier in May 1998 as Pain Therapeutics, focusing on opioids and chronic pain. Barbier first heard of the research led by Stanley M. Crain at the Albert Einstein College of Medicine in New York City around 1993. Crain invited Barbier to his lab and explained the potential pharmaceutical and financial benefits. In 1998, Barbier started Pain Therapeutics, Inc. in South San Francisco, California, with an initial investment of $1 million.
Name change
Following the fourth Food and Drug Administration (FDA) rejection of one of its experimental pain drugs, Remoxy, Pain Therapeutics announced in August 2018 it would reorganize the company to focus on products for treating and diagnosing Alzheimer's. In 2019, the company changed its name to Cassava Sciences.
On March 10, 2026, Cassava changed its name a second time to Filana Therapeutics. The name reflects its new goal of developing filamin A (FLNA)-targeted drugs for the treatment of brain diseases.